+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 1 Diabetes Drug Market by Insulin Type, Delivery Mode, Route of Administration, Treatment Line, Distribution Channel, End User, Patient Age Group - Global Forecast 2026-2032- Product Image
Type 1 Diabetes Drug Market by Insulin Type, Delivery Mode, Route of Administration, Treatment Line, Distribution Channel, End User, Patient Age Group - Global Forecast 2026-2032- Product Image
Sale

Type 1 Diabetes Drug Market by Insulin Type, Delivery Mode, Route of Administration, Treatment Line, Distribution Channel, End User, Patient Age Group - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4985893
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Type 1 Diabetes Drug Market is projected to reach USD 22.75 Billion in 2026. It is expected to continue growing at a CAGR of 9.32%, reaching USD 39.07 Billion by 2032.

The type 1 diabetes drug market is anchored by lifelong insulin replacement, expanding use of insulin analogs, and a rising clinical focus on disease-modifying therapies that address autoimmune beta-cell destruction. Verified epidemiology underscores the commercial and public health need: CDC data show that about 2 million people in the United States live with type 1 diabetes, including more than 300,000 children and adolescents, while global research published in The Lancet estimates millions of people worldwide are affected.

Demand is shaped by earlier diagnosis, pediatric incidence growth in several regions, broader access to continuous glucose monitoring and automated insulin delivery, and payer pressure for therapies that reduce severe hypoglycemia, diabetic ketoacidosis, and long-term complications. The market is also moving beyond glycemic control toward immune intervention, exemplified by U.S. FDA approval of teplizumab to delay stage 3 type 1 diabetes in eligible patients aged 8 years and older.

Transformative Shifts in the Type 1 Diabetes Drug Landscape

The most important shift in the type 1 diabetes drug landscape is the transition from insulin-only management toward a continuum that includes prevention, delay, precision dosing, and complication reduction. Rapid-acting and long-acting insulin analogs remain essential, while biosimilar and follow-on insulin products are increasing price competition and improving formulary flexibility in major markets.

At the same time, immune-modifying drugs, beta-cell preservation strategies, stem-cell-derived islet replacement, and encapsulation technologies are reshaping R&D priorities. Regulatory agencies are increasingly open to clinically meaningful endpoints such as delaying disease onset, reducing insulin dependency, preserving C-peptide, and improving time in range, which is shifting investment toward therapies that can change the natural history of type 1 diabetes.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across type 1 diabetes drug discovery, clinical development, and real-world disease management. AI models are used to analyze immunologic biomarkers, genetic risk scores, electronic health records, clinical trial datasets, and glucose data to identify patients at risk of progression and support more efficient trial recruitment.

In commercial care pathways, AI-enabled insulin decision support and automated insulin delivery algorithms can improve glucose control when integrated with CGM and pump ecosystems. For drug developers, AI strengthens pharmacovigilance, adherence analytics, and comparative effectiveness research, helping demonstrate outcomes that payers increasingly require for reimbursement and long-term access.

Key Regional Insights Across Major Markets

North America remains the most advanced region for type 1 diabetes drugs, led by the United States, where high diagnosis rates, specialty endocrinology networks, continuous glucose monitoring adoption, and reimbursement for advanced diabetes technologies support uptake of premium insulin analogs and immune-therapy innovation. Canada shows strong clinical guideline alignment and public health support, although provincial reimbursement variation influences access to insulin formulations, diabetes devices, and adjunct care services.

Europe benefits from structured diabetes registries, national health systems, pediatric diabetes programs, and broad use of biosimilar insulin in cost-containment strategies. Asia-Pacific is expanding its clinical relevance as China, India, Japan, Australia, and South Korea improve screening, pediatric endocrinology capacity, reimbursement pathways, and digital diabetes management. Latin America demonstrates rising need as Brazil and Mexico expand public-sector diabetes care, though affordability and procurement consistency remain important constraints. The Middle East, particularly high-income Gulf health systems, is investing in specialty diabetes centers, digital health, and prevention programs, while Africa faces the greatest access barriers due to insulin affordability, cold-chain requirements, trained specialist shortages, and inconsistent supply across many countries.

Key Group Insights for Strategic Market Expansion

The European Union is a critical policy and reimbursement bloc for type 1 diabetes drugs because centralized regulatory pathways, evolving health technology assessment reforms, pharmacovigilance standards, and biosimilar adoption influence pricing and access across member states. The G7 concentrates advanced R&D capacity, premium treatment adoption, pediatric diabetes expertise, and payer scrutiny, making it central to evidence generation for insulin analogs, immunotherapies, beta-cell preservation, and beta-cell replacement programs.

BRICS countries represent high-volume long-term treatment expansion potential, particularly through China, India, and Brazil, where expanding healthcare coverage, domestic biologics capacity, and improving diagnosis can increase treated populations, although affordability remains a defining access issue. ASEAN markets are improving diabetes infrastructure and digital health adoption but remain price sensitive, requiring scalable insulin access models and clinician education. GCC countries are investing in specialty care, chronic disease management, and connected diabetes technologies, supporting higher adoption of advanced therapies when evidence is compelling. NATO overlap with North America and Europe reinforces high standards for supply chain resilience, regulatory quality, biologics manufacturing security, and continuity of essential insulin supply.

Key Country Insights in the Type 1 Diabetes Drug Market

The United States is the leading commercial market due to high treatment intensity, innovation adoption, strong clinical trial activity, and regulatory precedent for disease-delaying therapy. Canada, the United Kingdom, Germany, France, Italy, and Spain benefit from established endocrinology services, pediatric diabetes networks, and guideline-driven care, though reimbursement decisions are closely tied to cost-effectiveness evidence, real-world outcomes, and budget impact. Russia and Mexico present sustained demand for insulin access and affordability, with public procurement, domestic supply priorities, and distribution reliability playing significant roles.

China and India offer major long-term opportunity as diagnosis improves, healthcare investment grows, and specialist networks expand, but affordability, awareness, rural access, and availability of advanced diabetes technologies remain barriers. Japan, Australia, and South Korea show strong adoption of advanced diabetes technologies, favorable clinical infrastructure, and high standards for post-market safety monitoring. Brazil is the most important Latin American country in this set, driven by public-sector insulin access, private healthcare growth, diabetes advocacy, and increasing attention to pediatric and adolescent type 1 diabetes care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that generate measurable clinical value beyond HbA1c, including improved time in range, lower severe hypoglycemia, reduced diabetic ketoacidosis, preserved beta-cell function, delayed progression to symptomatic disease, and better quality of life. Evidence packages should integrate randomized controlled trials with real-world data from CGM, pump, claims, electronic health record, and registry sources.

Organizations should also strengthen access strategies through tiered pricing, biosimilar partnerships, patient support programs, clinician education, and cold-chain reliability in emerging markets. For innovation portfolios, the highest-value opportunities include immune modulation, beta-cell replacement, precision insulin delivery, and AI-enabled adherence and risk stratification tools that align drug benefits with payer-relevant outcomes and practical care delivery.

Research Methodology

This executive summary is based on secondary research using verified sources such as public health agencies, regulatory databases, clinical trial registries, peer-reviewed journals, diabetes association guidance, and publicly available healthcare policy documents. The analysis prioritizes evidence from organizations including the CDC, WHO, U.S. FDA, EMA, International Diabetes Federation, and leading clinical publications.

Market interpretation applies cross-validation across epidemiology, treatment guidelines, reimbursement trends, product approvals, pipeline activity, clinical endpoints, digital diabetes adoption, and regional access conditions. Insights are structured to support strategic planning for type 1 diabetes drug developers, insulin manufacturers, biosimilar entrants, medtech partners, payers, and healthcare investors without relying on market sizing, market share, or forecasting assumptions.

Conclusion

The type 1 diabetes drug market is entering a new phase in which insulin remains foundational while disease modification, digital integration, and precision care create differentiated strategic pathways. The approval of immune therapy to delay disease onset has validated a broader preventive and interventional model for type 1 diabetes treatment.

Future leadership will depend on demonstrating durable clinical outcomes, expanding equitable access, ensuring reliable insulin supply, and combining drug innovation with data-driven care delivery. Organizations that align biologic innovation, AI-enabled evidence generation, and region-specific reimbursement strategies will be best positioned in this evolving market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Type 1 Diabetes Drug Market, by Insulin Type
7.1. Intermediate-Acting
7.2. Long-Acting
7.3. Rapid-Acting
7.4. Short-Acting
8. Type 1 Diabetes Drug Market, by Delivery Mode
8.1. Pen
8.2. Pump
8.3. Syringe
9. Type 1 Diabetes Drug Market, by Route Of Administration
9.1. Subcutaneous
9.2. Intravenous
10. Type 1 Diabetes Drug Market, by Treatment Line
10.1. First-Line
10.2. Second-Line
10.3. Third-Line And Beyond
11. Type 1 Diabetes Drug Market, by Distribution Channel
11.1. Offline
11.2. Online
12. Type 1 Diabetes Drug Market, by End User
12.1. Clinics
12.2. Home Care
12.3. Hospitals
13. Type 1 Diabetes Drug Market, by Patient Age Group
13.1. Adult
13.2. Geriatric
13.3. Pediatric
14. Asia-Pacific Type 1 Diabetes Drug Market
15. North America Type 1 Diabetes Drug Market
16. Latin America Type 1 Diabetes Drug Market
17. Europe Type 1 Diabetes Drug Market
18. Middle East Type 1 Diabetes Drug Market
19. Africa Type 1 Diabetes Drug Market
20. ASEAN Type 1 Diabetes Drug Market
21. GCC Type 1 Diabetes Drug Market
22. European Union Type 1 Diabetes Drug Market
23. BRICS Type 1 Diabetes Drug Market
24. G7 Type 1 Diabetes Drug Market
25. NATO Type 1 Diabetes Drug Market
26. United States Type 1 Diabetes Drug Market
27. Canada Type 1 Diabetes Drug Market
28. Mexico Type 1 Diabetes Drug Market
29. Brazil Type 1 Diabetes Drug Market
30. United Kingdom Type 1 Diabetes Drug Market
31. Germany Type 1 Diabetes Drug Market
32. France Type 1 Diabetes Drug Market
33. Russia Type 1 Diabetes Drug Market
34. Italy Type 1 Diabetes Drug Market
35. Spain Type 1 Diabetes Drug Market
36. China Type 1 Diabetes Drug Market
37. India Type 1 Diabetes Drug Market
38. Japan Type 1 Diabetes Drug Market
39. Australia Type 1 Diabetes Drug Market
40. South Korea Type 1 Diabetes Drug Market
41. Competitive Landscape
41.1. Market Concentration Analysis, 2025
41.1.1. Concentration Ratio (CR)
41.1.2. Herfindahl Hirschman Index (HHI)
41.2. Recent Developments & Impact Analysis, 2025
41.3. Product Portfolio Analysis, 2025
41.4. Benchmarking Analysis, 2025
42. Company Profiles
42.1. Adocia
42.2. Arecor Therapeutics PLC
42.3. AstraZeneca PLC
42.4. Biocon Limited
42.5. Bristol-Myers Squibb Company
42.6. Civica, Inc.
42.7. Diasome Pharmaceuticals Inc.
42.8. Eli Lilly and Company
42.9. Gan & Lee Pharmaceuticals Co., Ltd.
42.10. GlaxoSmithKline PLC
42.11. Johnson & Johnson Services Inc.
42.12. Lexicon Pharmaceuticals Inc.
42.13. Lupin Limited
42.14. MannKind Corporation
42.15. Merck & Co. Inc.
42.16. Mylan N.V.
42.17. Novartis AG
42.18. Novo Nordisk A/S
42.19. Pfizer Inc.
42.20. Provention Bio Inc.
42.21. Sandoz Group AG
42.22. Sanofi S.A.
42.23. Sun Pharmaceutical Industries Ltd.
42.24. Teva Pharmaceutical Industries Ltd.
42.25. Viatris Inc.
42.26. Zealand Pharma A/S
List of Figures
FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INTERMEDIATE-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INTERMEDIATE-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INTERMEDIATE-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LONG-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LONG-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LONG-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL RAPID-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL RAPID-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL RAPID-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SHORT-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SHORT-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SHORT-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PUMP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PUMP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PUMP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL SECOND-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SECOND-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SECOND-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 99. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 101. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 102. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 103. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 104. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 105. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 115. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 117. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 118. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 119. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 120. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 123. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 125. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 126. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 128. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 131. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 133. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 134. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 136. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 147. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 149. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 150. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 152. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 157. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 158. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 159. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 160. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 163. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 165. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 166. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 168. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 171. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 172. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 173. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 174. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 176. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 179. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 180. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 181. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 182. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 184. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 187. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 189. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 190. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 191. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 192. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 195. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 197. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 198. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 200. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 203. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 204. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 206. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 208. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 211. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 213. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 214. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 216. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 217. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 218. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 219. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 220. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 221. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 222. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 224. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 227. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 228. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 229. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 230. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 231. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 232. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 233. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 234. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 235. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 237. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 238. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 240. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 241. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 243. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 244. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 245. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 246. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 248. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 249. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 251. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 252. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 253. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 254. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 255. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 256. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 257. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 258. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 259. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 261. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 262. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 263. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 264. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 265. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 266. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 267. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 268. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 269. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 270. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 271. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 272. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 273. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 274. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 275. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 276. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 277. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 278. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 279. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 280. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 281. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 282. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 283. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 284. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
TABLE 285. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 286. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 287. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
TABLE 288. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 289. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 290. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Type 1 Diabetes Drug market report include:
  • Adocia
  • Arecor Therapeutics PLC
  • AstraZeneca PLC
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Civica, Inc.
  • Diasome Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals Co., Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Lexicon Pharmaceuticals Inc.
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Provention Bio Inc.
  • Sandoz Group AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zealand Pharma A/S

Table Information

Report AttributeDetails
No. of Pages186
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 22.75 Billion
Forecasted Market Value ( USD ) by 2032 $ 39.07 Billion
Compound Annual Growth Rate9.3%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Insulin Patch Pumps Market by Product Type, Diabetes Type, Operation Mode, Wear Duration, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Insulin Patch Pumps Market by Product Type, Diabetes Type, Operation Mode, Wear Duration, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Insulin Storage System Market by Product Type, Storage Mode, Portability, Component, Application - Global Forecast 2026-2032 - Product Image

Insulin Storage System Market by Product Type, Storage Mode, Portability, Component, Application - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Non-Insulin Diabetes Therapeutics - Global Strategic Business Report - Product Image

Non-Insulin Diabetes Therapeutics - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Human Insulin - Global Strategic Business Report - Product Image

Human Insulin - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Insulin Resistance Market Size and Share Outlook Report: Forecast Trends and Growth Analysis (2025-2034) - Product Image

Insulin Resistance Market Size and Share Outlook Report: Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From

About the Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat Type 1 Diabetes, an autoimmune disorder in which the body's immune system attacks the cells that produce insulin. These drugs are used to help regulate blood sugar levels and reduce the risk of complications associated with the disease. Commonly used Type 1 Diabetes Drugs include insulin, sulfonylureas, meglitinides, and GLP-1 agonists. These drugs are typically administered orally or through injection. The Type 1 Diabetes Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.